Talazoparib launch time and purchasing channels in China

Talazoparib/Talazoparib As a new type of PARP inhibitor, it has been officially approved for marketing in China on October 29, 2024, with the trade name "Talazoparib". This time point means that for the first time, Chinese patients can directly obtain original drugs in China, instead of relying entirely on imports or overseas channels. When original drugs are launched on the market, the price is usually relatively high. Currently in the Hong Kong market, a box of 1 mg 30 pills may cost more than 50,000 yuan, while the price of 0.25 mg 30 pills sold in Europe is about more than 10,000 yuan per box. Affected by exchange rate changes, prices fluctuate.

At the same time, generic drugs have been released in some overseas regions, such as the generic version produced by a Laos pharmaceutical factory. Each box of 1mg*30 pills may be sold for more than 1,000 yuan. The ingredients are basically the same as the original drugs, providing patients with a more cost-effective choice. In terms of domestic purchase channels, original drugs are currently mainly obtained through regular hospital pharmacies and some approved imported drug sales platforms. Since it has been on the market for a short time and has not yet been fully rolled out, patients must obtain a doctor's prescription before taking the medicine and purchase it through formal channels to avoid quality and safety issues caused by purchasing medicines through informal channels.

In the future, as talazoparib is gradually included in hospital pharmacy catalogs in China, and with the promotion of the State Food and Drug Administration and the Medical Insurance Bureau, its accessibility and payment policies are expected to improve. For qualified patients, they can also choose to purchase drugs through overseas channels, such as through cross-border pharmacies or authorized platforms of international pharmaceutical companies, but they need to pay attention to customs policies and drug authenticity issues.

Overall, the launch of talazoparib in China has brought new treatment hope to patients. Although price is still a common concern for patients, with the addition of generic drugs and the gradual advancement of medical insurance policies, the popularity of its clinical application is expected to increase rapidly.

Reference materials:https://www.talzenna.com/